ACY-738

CAS No. 1375465-91-0

ACY-738( ACY738 | ACY 738 )

Catalog No. M11552 CAS No. 1375465-91-0

ACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 53 In Stock
5MG 87 In Stock
10MG 159 In Stock
25MG 267 In Stock
50MG 438 In Stock
100MG 582 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ACY-738
  • Note
    Research use only, not for human use.
  • Brief Description
    ACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs.
  • Description
    ACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs; induces dramatic increase in α-tubulin acetylation in brain and stimulates mouse exploratory behaviors; increases the innervation of the neuromuscular junctions in the gastrocnemius muscle and improves the motor and sensory nerve conduction in the mutant HSPB1-induced CMT2 mouse model.Depression Preclinical.
  • In Vitro
    ACY-738 (2.5?μM) increases the acetylated (lysine 40) fraction of α-tubulin in RN46A-B14 cells. ACY-738 (10 μM) induces cell death comparable to LBH589 and FK228.
  • In Vivo
    ACY-738 (5?mg/kg) leads to significant increase in α-tubulin acetylation in whole-brain lysates. ACY-738 (50?mg/kg) fails to produce an enhancement of locomotor activity in WT mice tested in a home cage environment. ACY-738 (5 mg/kg) reaches a maximum plasma concentration of 1310 ng/mL at 0.0830 h following treatment. ACY-738 (5 mg/kg BW) alters BM B cell differentiation, but shows no significant effect on IgG and C3 deposition in NZB/W mice. ACY-738 (20 mg/kg) significantly attenuates the severity of proteinuria in NZB/W F1 mice. ACY-738 (5 mg/kg) shows a significant decrease in anti-dsDNA production in NZB/W mice as they aged. ACY-738 (5, 20 mg/kg) attenuates sera IL-1β production as the NZB/W mice aged. ACY-738 (5 mg/kg) significantly reduces glomerular IL-6 and IL-10 mRNA levels by more than 50% while treatment with 20 mg/kg ACY-738 reduced IL-6 and IL-10 mRNA to non-detectable levels.
  • Synonyms
    ACY738 | ACY 738
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC6
  • Research Area
    Neurological Disease
  • Indication
    Depression

Chemical Information

  • CAS Number
    1375465-91-0
  • Formula Weight
    270.2866
  • Molecular Formula
    C14H14N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 32 mg/mL
  • SMILES
    O=C(C1=CN=C(NC2(C3=CC=CC=C3)CC2)N=C1)NO
  • Chemical Name
    5-Pyrimidinecarboxamide, N-hydroxy-2-[(1-phenylcyclopropyl)amino]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jochems J, et al. Neuropsychopharmacology. 2014 Jan;39(2):389-400. 2. Regna NL, et al. Clin Immunol. 2016 Jan;162:58-73. 3. Benoy V, et al. Neurotherapeutics. 2017 Apr;14(2):417-428.
molnova catalog
related products
  • Pyroxamide

    Pyroxamide is an histone deacetylases (HDACs) inhibitor with antineoplastic properties ( HDAC1;IC50: 0.1-0.2 μM).

  • Resminostat

    A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM.

  • Panobinostat

    A potent, broad-spectrum HDAC inhibitor with IC50 of 5-20 nM in cell-free assyas.